Gastroesophageal Junction Adenocarcinoma – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030


 Gastroesophageal junction adenocarcinoma is a carcinoma in which the epicenter of the tumor is located within the GEJ region and remains a significant clinical problem that increases the disease burden with a poor prognosis. Most patients present with advanced disease, and less than 50% undergo curative treatment. Tumor infiltration of the proximal or distal resection margin has diminished survival in most series. The Siewert classification is applied to adenocarcinomas located within 5 cm above or below the GEJ. The GEJ adenocarcinomas are classified into three types as follows. Type I, which is located 1–5 cm above the GEJ, is adenocarcinoma of the distal esophagus. Type II is true carcinoma of cardia centered between 1 cm above and 2 cm below the GEJ. Type III is subcardial carcinoma located 2–5 cm below the GEJ. Adenocarcinoma of the gastroesophageal junction (GEJ) remains a significant clinical problem increasing in incidence and is associated with a poor prognosis. Most patients present with advanced disease, and less than 50% undergo curative treatment.

 

The incidence of Gastroesophageal junction adenocarcinoma ranges from 2.8 to 3.9 per 100,000 population in the USA.

 

The competitive landscape of Gastroesophageal Junction Adenocarcinoma includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Gastroesophageal Junction Adenocarcinoma across the 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Gastroesophageal Junction Adenocarcinoma Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Gastroesophageal Junction Adenocarcinoma– Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          EP-104IAR        Akeso   Phase 3

2          DS-8201a         Daiichi Sankyo, Inc.       Phase 2

3          Bemarituzumab Amgen  Phase 3

4          MEDI4736 + tremelimumab       MedImmune LLC           Phase 2

5          Avelumab         EMD Serono Research & Development Institute, Inc.       Phase 3

6          Ramucirumab and Paclitaxel      Eli Lilly and Company    Phase 2

7          Andecaliximab and Nivolumab    Gilead Sciences            Phase 2

8          QL1604 Qilu Pharmaceutical Co., Ltd.     Phase 3

9          Atezolizumab and Trastuzumab Hoffmann-La Roche      Phase 2

10        CS1001            CStone Pharmaceuticals            Phase 3

Continued

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypoglycemia and severe
Read more